Library

Protocol

SLU-PP-332 (5mg Vial)

Complete dosage protocol and reconstitution guide for SLU-PP-332 (5mg Vial).

Updated November 26, 2025 Research guide Research information only
Open calculator preset Build protocol outline TNHL options
Educational reference only. TNHL calculates and organizes user-entered values; it does not diagnose, prescribe, recommend doses, or replace guidance from a qualified professional.
MechanismPRECLINICAL RESEARCH COMPOUND: SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors (ERRα/β/γ) studied exclusively in murine models for its ability to activate an aerobic-exercise gene program, enhance mitochondrial function, and improve endurance and cardiometabolic phenotypes [1] [2] [3] . No human trials have been conducted as of November 2025.
DosingReference dose shown on this page: 1.67 mg.
ReconstitutionAdd 3.0 mL diluent to a 5 mg vial.
StorageLyophilized: −20 °C (−4 °F) ; reconstituted: 2–8 °C (35.6–46.4 °F) .

Calculator preset

Run the vial math before tracking.

At ~1.67 mg/mL, 1 unit ~ 16.67 mcg ; 625 mcg ~ 37.5 units and 1,250 mcg ~ 75 units on a U-100 syringe.

Calculate this vial

01 · At a glance

Quickstart Highlights

PRECLINICAL RESEARCH COMPOUND: SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors (ERRα/β/γ) studied exclusively in murine models for its ability to activate an aerobic-exercise gene program, enhance mitochondrial function, and improve endurance and cardiometabolic phenotypes [1] [2] [3] . No human trials have been conducted as of November 2025. This educational protocol reflects published murine regimens using intraperitoneal administration. Evidence Base: Preclinical only—in vivo mouse studies with intraperitoneal dosing (25–50 mg/kg twice daily).

ReconstituteAdd 3.0 mL bacteriostatic water → ~ 1.67 mg/mL concentration. Murine
Reference doseReference dose shown on this page: 1.67 mg.
Easy measuringAt ~1.67 mg/mL, 1 unit ~ 16.67 mcg ; 625 mcg ~ 37.5 units and 1,250 mcg ~ 75 units on a U-100 syringe.
StorageLyophilized: −20 °C (−4 °F) ; reconstituted: 2–8 °C (35.6–46.4 °F) .
Start with sterile preparation, storage, and injection-site basics before using any calculator output. TNHL is a tracking and education tool only.

02 · Dosing & reconstitution

Dosing & Reconstitution Guide

A practical calculator-ready setup based on the imported protocol reference. Use these values as a math starting point, then verify every entry against your own vial, diluent, and professional guidance.

Standard / Gradual Titration

Phase / setup Dose & frequency Volume / units
Reference setup1.67 mg100.2 units on a U-100 syringe
Vial math5 mg + 3.0 mLAt ~1.67 mg/mL, 1 unit ~ 16.67 mcg ; 625 mcg ~ 37.5 units and 1,250 mcg ~ 75 units on a U-100 syringe.
PlanningUser-entered scheduleUse the calculator and tracker to estimate doses per vial and inventory needs

Reference dose shown on this page: 1.67 mg.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light.

03 · What you'll need

Supplies Needed

Keep this as a planning checklist. TNHL does not sell or verify supplies on this page, and no supplier quality claims are made here.

Peptide Vials 8 weeks ≈ 25 vials
  • 12 weeks ≈ 39 vials
  • 16 weeks ≈ 53 vials
Insulin Syringes Per week: 14 syringes (2/day)
  • 8 weeks: 112 syringes
  • 12 weeks: 168 syringes
  • 16 weeks: 224 syringes
Bacteriostatic Water Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (25 vials): 75 mL → 8 × 10 mL bottles
  • 12 weeks (39 vials): 117 mL → 12 × 10 mL bottles
  • 16 weeks (53 vials): 159 mL → 16 × 10 mL bottles
Alcohol Swabs One for the vial stopper + one for the injection site each administration.
  • Per week: 28 swabs (4/day)
  • 8 weeks: 224 swabs → recommend 3 × 100-count boxes
  • 12 weeks: 336 swabs → recommend 4 × 100-count boxes
  • 16 weeks: 448 swabs → recommend 5 × 100-count boxes

Protocol Overview

  • Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL).
  • Storage: Lyophilized frozen; reconstituted refrigerated.

Dosing Protocol

  • Murine-equivalent dosing framework.
  • Initial Phase (Weeks 1–2): 1250 mcg daily (625 mcg per injection, twice daily).
  • Maintenance Phase (Weeks 3–8): 2500 mcg daily (1250 mcg per injection, twice daily).
  • Frequency: Twice per day, reflecting published murine regimens [1] [2] [3] .
  • Route: Intraperitoneal (as studied in preclinical models).
  • Timing: Consistent intervals between administrations.

Storage Instructions

  • Lyophilized: −20 °C (−4 °F) ; reconstituted: 2–8 °C (35.6–46.4 °F) .
  • Storage: Lyophilized frozen; reconstituted refrigerated.
  • Keep mixed and unmixed items clearly labeled so inventory and dose logs stay accurate.

04 · Good to know

Important Notes

  • This SLU-PP-332 page is for educational research organization only.
  • Confirm route, dose, contraindications, monitoring, storage, and cycle decisions with qualified professional guidance.
  • Use sterile technique, rotate sites when applicable, and log missed doses, reactions, and inventory changes.

05 · How it works

How This Works

PRECLINICAL RESEARCH COMPOUND: SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors (ERRα/β/γ) studied exclusively in murine models for its ability to activate an aerobic-exercise gene program, enhance mitochondrial function, and improve endurance and cardiometabolic phenotypes [1] [2] [3] .

No human trials have been conducted as of November 2025.

This educational protocol reflects published murine regimens using intraperitoneal administration.

The library page pairs that educational context with calculator-ready vial math, so users can understand the protocol structure and then track their own entered values in one place.

06 · Daily habits

Lifestyle Factors

  • Keep meals, training, sleep, and recovery notes in the journal so trends are easier to review.
  • Track body metrics only if they are relevant to the user's goal and approved data sources.
  • Use consistent timing and logging habits so adherence data is meaningful.

07 · What to expect

Potential Benefits & Side Effects

  • Findings from murine studies only.
  • Metabolic effects: Enhanced mitochondrial function, increased fatty-acid oxidation, improved glucose tolerance in diet-induced obese mice [2] .
  • Cardiac benefits: Ameliorated heart failure through enhanced cardiac fatty-acid metabolism and mitochondrial function in preclinical models [3] .
  • Endurance enhancement: Increased treadmill running capacity and muscle oxidative capacity in mice [1] .
  • Renal effects: Reversed mitochondrial dysfunction and inflammation in aging kidney models [4] .
  • Human safety unknown: No data on human tolerability, pharmacokinetics, or adverse effects exist.

08 · Technique

Injection Technique

Pre-injection preparation
  • Wash hands with soap and water.
  • Wipe the vial stopper and chosen site with alcohol, then let both dry.
  • Confirm the vial concentration, calculator result, and intended draw amount before loading the syringe.
Injection procedure
  • Use the route and needle technique directed by a qualified professional or product instructions.
  • For subcutaneous injections, rotate sites and inject slowly to limit leakage and irritation.
  • Do not reuse needles or syringes.
Post-injection care
  • Dispose of sharps in a puncture-resistant container.
  • Return stored items promptly to the correct temperature.
  • Log dose, site, date, time, inventory change, and any observation.

09 · Evidence

References

TNHL options

Peptide collections stay passive.

Open the TNHL Stan Store option that fits the order size. Product details, checkout, and fulfillment stay off-site.